


EVALUATION OF EFFECTIVENESS OF DARUNAVIR/COBICISTAT MONOTHERAPY IN HIV PATIENTS.

P. NIETO GÓMEZ¹, P. MORENO¹, M. Valle Corpas¹, I. Casas Hidalgo¹, A. Rodríguez Delgado¹, R. Álvarez Sánchez¹, C. García Fernández¹.
¹Hospital Campus de la Salud, Hospital Pharmacy, Granada, Spain.

OBJECTIVE

To analyze the virological and immune response in patients on darunavir/cobicistat monotherapy.

RESULTS



MATERIAL AND METHODS

We made a search of clinical variables as well as results of analytical tests. The variables included in this study were sex, age, viral loads at the beginning of the treatment and at month 6 and 12 and percentage of TCD4 lymphocytes in blood samples.

CONCLUSIONS

Based on these findings we can affirm that monotherapy is a great strategy in patients who already have a good control of the HIV infection. Immune and virologic response is difficult to achieve after 12 months in patients who begin the treatment without them.

DISCUSSION

Patients (n=30) had a mean age of 50.2 ± 11.6 years and 66.6% were men.

Patients without virological response were 20% at the beginning of treatment, 13% at month 6 and 10% at month 12.

Patients without immune response at the beginning represented 36.7% and they did not achieve it during 12 months. Every patient with immune response at the beginning of the treatment maintained this response.

ACKNOWLEDGEMENTS

None